RNU6-345P

Across TCGA pan-cancer cohorts, RNU6-345P RNA is linked to patient survival in 6 of 34 cancer types, making it the most broadly survival-associated RNU6-345P data layer.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher RNU6-345P RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RNU6-345P expression acts as an unfavorable survival marker, although some lineages such as KIRC show a favorable association.

STAD, PCPG, and GBM are the cancer types where RNU6-345P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Tertile	All	0.228	0.723	<.001	45	view →
PCPG	DFS	Tertile	All	0.370	0.928	<.001	45	view →
GBM	DFS	Tertile	All	0.058	0.297	<.001	18	view →
THCA	DFS	Tertile	All	0.788	0.918	.006	12	view →
KIRC	DFS	Tertile	All	1.000	0.864	.016	12	view →
UCEC	OS	Tertile	All	0.855	0.927	.031	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RNU6-345P–STAD (DFS)

Open the STAD breakdown →